Rising prevalence of genetic respiratory disorders, expanding healthcare infrastructure, and strong R&D investments fuel sustained market growth worldwide.Austin, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) ...
Quantitative CT in AATD linked airway wall thickening and bronchiectasis to lung function, while wall thickness best ...
Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has cleared its ...
Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...
Earlier this month, CRISPR Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, ...
Beam Therapeutics shares climbed after the company said it plans to file an application for its risto-cel treatment and had reached alignment with the Food and Drug Administration on potential ...
Beam Therapeutics shares are popping on Monday after the company laid out a series of pipeline updates and strategic ...
Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 ...
This Somerville biotech company is gearing up to lay off more than 80 employees in Massachusetts this year. Here's what we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results